News

AZoLifeSciences on MSN7d
Study Identifies SMARCB1 and MEOX2 Genes as Growth Regulators of Lung Cancers
A Cancer Gene Therapy study reveals that MEOX2 promotes lung cancer progression while SMARCB1 acts as a tumor suppressor, ...
The EMBO Journal28d
Individual cristae within the same mitochondrion display different membrane potentials and are functionally independent
A. Images of IMM in living HeLa, L6, and H1975 cells, stained with 10‐N‐nonyl acridine orange (NAO). NAO preferentially binds phospholipids in the IMM, such as cardiolipin. Arrowheads indicate cristae ...
Frontiers21d
A trispecific antibody targeting EGFR/cMET/VEGF-A demonstrates multiple mechanisms of action to inhibit wild-type and mutant NSCLC animal models
TAVO412 also demonstrated EGFR and cMET receptor degradation in vivo. Mice bearing HCC827 or NCI-H1975 tumors were treated with TAVO412 twice. The tumors were collected 24 h after the second dose. The ...
C&EN8d
Enhanced Antitumor Activity of Cetuximab in Combination with the Jak Inhibitor CYT387 against Non-Small-Cell Lung Cancer with Various Genotypes
In resistant cell lines (H1975 and H1650), the efficacy of cetuximab was increased when combined with CYT387, whereas CYT387 alone in low doses exhibited little effect on NSCLC cell proliferation. In ...
Frontiers28d
GART promotes the proliferation and migration of human non-small cell lung cancer cell lines A549 and H1299 by targeting PAICS-Akt-β-catenin pathway
The lung cancer cell lines (H522, HCC827, H1975, A549, and H1299) and human normal lung epithelial cells (BEAS-2B) were purchased from iCell Bioscience Inc (Shanghai, China) and cultured in Dulbecco’s ...
ascopubs.org9d
Digital profiling of tumor-derived extracellular vesicle-RNA: A sensitive approach for early detection of EGFR mutations in osimertinib-resistant non-small cell lung cancer.
Survival outcomes in locally advanced inoperable NSCLC patients converted to resectable disease by neoadjuvant therapy. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...
ascopubs.org9d
Novel potent and selective fourth-generation inhibitors targeting EGFR for NSCLC therapy.
Advancing evidence-based NSCLC testing and treatment across academic and community-based settings. Final overall survival analysis for a phase 3 randomized trial comparing afatinib to chemotherapy in ...
C&EN6d
Potent, Selective, and Cell Active Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor Developed by Structure-Based Virtual Screening and Hit Optimization
‡ Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CAS), Shanghai 201203, China § CAS Key Laboratory of ...
World Scientific29d
Comparison of Immunomodulatory and Anticancer Activities in Different Strains of Tremella fuciformis Berk
Department of Health and Nutrition Biotechnology, Asia University, Taichung, Taiwan, R.O.C. Department of Life Science, College of Life Science, National Taiwan ...